System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Dr Iñigo Lozano, FESC, FACC is an expert in Cardiology at Instituto de Investigación Sanitaria del Principado de Asturias (Spain). As of October 2026, ScienceLeadR ranks Iñigo Lozano in the top 1% of experts in Spain for Coronary Disease and Myocardial Ischemia. Iñigo Lozano has authored 268 publications, the most recent in 2026, and is an investigator in 12 clinical trials, 1 of them ongoing. SLR score: 899 (community average: 125). How the SLR is computed.

LeadR Profile

Dr Iñigo Lozano, FESC, FACC Instituto de Investigación Sanitaria del Principado de Asturias Spain
899 ScienceLeadR Reputation 899

Unlock

Register Login
Network Map

Cardiology

Subspecialties: Public Health - Internal Medicine - Pharmacy

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2005 - 2026
Source: PubMed

Instituto de Investigación Sanitaria del Principado de Asturias

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 268

Citations

Citations: 3 985 1st author: 119 Last author: 12 Unique author: 2

Main journals

Rev Esp Cardiol 54
JACC Cardiovasc Interv 33
Rev Esp Cardiol (Engl Ed) 29
J Am Coll Cardiol 22
Int J Cardiol 16

Best Journals

N Engl J Med 5
Eur Heart J 3
Lancet 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
VerifyNow in acute coronary syndrome: design of the EPIC17-VERONICA trial to optimize platelet inhibition.
PMID 42745741 — research design, hemorrhage, ticagrelor, acute coronary syndrome, platelet aggregation, therapeutics, blood platelets		REC Interv Cardiol20250
Don't ask FFR to do what it cannot: flow limitation, not plaque instability - The risk of discrediting FFR by expecting the impossible.
PMID 42660322 — cardiology		Int J Cardiol20260
IVUS-Guided versus Angiography-Guided PCI in Unprotected Left Main Coronary Disease.
PMID 41911017 — stroke, coronary artery disease, myocardial infarction, incidence, angiography, arteries, coronary disease		N Engl J Med Top journal20261
New risk classification adapting SCAI shock stages to patients with pulmonary embolism (RISA-PE).
PMID 39315892 — embolism, incidence, cardiovascular diseases, classification, pulmonary embolism, therapeutics		Minerva Cardiol Angiol20246
Validation of the Zwolle Risk Score in STEMI Patients Undergoing Primary PCI: Insights from the ISCAS-STEMI COVID-19 Registry.
PMID 40247796 — registries, mortality, st elevation myocardial infarction, covid-19, pandemics		Curr Vasc Pharmacol20250

Clinical Studies 12

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

N/A 9
Phase 3 2
Phase 4 1

By status:

Completed 7
Active not recruiting 2
Unknown 2
Recruiting 1

By type:

Interventional 7
Observational 5

By Monocentric/Multicentric:

monocentric 6
multicentric2to4 0
multicentric5to9 0
multicentricup10 6

Main Topics

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Cross over Study of Coronary Risk Factors With a Polypill
NCT05030818 — hypertension, cholesterol, ldl, coronary artery disease, pharmaceutical preparations, cross-over studies, ramipril, aspirin, arteries, cholesterol, risk factors, blood platelets, atorvastatin, single-pill combination		Phase 4Recruiting2022

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS